NYXH (Nyxoah, S.A.) Gross Profit Margin

The gross profit margin reflects production efficiency dynamics, where 38.10 serves as the current parameter value. Nyxoah S.A. management ensures transparency regarding FDA certification, although capital expenditure risks persist. Nyxoah S.A. is implementing innovative neurostimulators to treat apnea, expanding its global reach. However, success depends on the pace of commercialization and the willingness of insurance companies to provide reimbursement for treatment.
Analytical breakdowns and data insights for company Nyxoah (NYXH)

The gross margin, equal to 38.10, measures the portion of revenue remaining after covering direct production costs, which determines the efficiency of capital management. An analysis of the gross margin from sales on GURU.Markets confirms the resilience of Nyxoah S.A. (NYXH), as steady demand for unique medtech solutions minimizes macroeconomic risks, turning this indicator into a reliability marker for a defensive asset.